Actively Recruiting
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Led by Novartis Pharmaceuticals · Updated on 2026-04-01
40
Participants Needed
8
Research Sites
212 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation.
CONDITIONS
Official Title
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a solid tumor confirmed to have the BRAF V600E mutation by a local lab test
- Have at least one measurable tumor lesion as defined by RECIST v1.1
- Have not been treated with dabrafenib or trametinib before, or have stopped these treatments for other cancers more than 1 year ago
- Are able to provide scans for central imaging review
You will not qualify if you...
- Have melanoma, non-small cell lung cancer, anaplastic thyroid cancer, biliary tract cancer, glioma, or colorectal cancer
- Have any contraindications to receive dabrafenib or trametinib based on local guidelines
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Lundquist Inst BioMed at Harbor
Torrance, California, United States, 90509-2910
Actively Recruiting
2
Rocky Mountain Cancer Centers
Denver, Colorado, United States, 80218
Actively Recruiting
3
Johns Hopkins University
Washington D.C., District of Columbia, United States, 20016
Actively Recruiting
4
Duke Clinical Research Institute
Durham, North Carolina, United States, 27704
Actively Recruiting
5
Oncology Hematology Care Inc
Cincinnati, Ohio, United States, 45242
Actively Recruiting
6
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
7
El Paso Texas Oncology
El Paso, Texas, United States, 79902
Actively Recruiting
8
Texas Oncology San Antonio
San Antonio, Texas, United States, 78258
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here